Schweizerischer Nationalfonds / Fonds national suisse
Breath analysis to monitor health status in intensive care
mehr
Storys zum Thema Diabetes
11FDI World Dental Federation releases powerful video message unifying voices in celebration of World Oral Health Day
mehrEpitomee® announces the filing of a novel Weight Loss Capsule for FDA clearance
Caesarea, Israel (ots/PRNewswire) - Epitomee® (TASE: EPIT) announced today that on February 27, 2024, it has submitted its Weight Loss Capsule for FDA clearance in the USA, reaching a significant milestone in the company's journey. The Epitomee® capsule offers an innovative, orally administered, drug free, and clinically proven as effective and safe solution, for ...
mehrFDI World Dental Federation calls for global leaders to prioritise action against oral diseases at major UN meeting on health / Call issued on World Oral Health Day, as data shows oral diseases impact nearly half the world's population
mehrWegovy(TM) Demonstrated Significant and Sustained Weight Loss in Two-Year Study in Adults With Obesity
Bagsværd, Denmark (ots/PRNewswire) - - The STEP 5 trial demonstrated an average weight loss of 15.2% with Wegovy(TM) at 104-weeks when used with a reduced calorie meal plan and increased physical activity vs. 2.6% with placebo - The trial also showed that 77.1% of study participants who received Wegovy(TM) lost at ...
mehrthe International Diabetes Federation
Diabetes is "a pandemic of unprecedented magnitude" now affecting one in 10 adults worldwide, reveals the International Diabetes Federation
Brussels (ots/PRNewswire) - New figures from the International Diabetes Federation reveal that 537 million adults around the globe are living with diabetes The International Diabetes Federation (IDF) has released new figures showing that 537 million adults are now living with diabetes worldwide - a rise of 16% (74 ...
mehrRoche and the Zur Rose Group announce collaboration to offer innovative health journeys for people living with diabetes
Basel, Switzerland (ots/PRNewswire) - - Roche, a world leader in integrated Personalised Diabetes Management, and the Zur Rose Group, provider of a European digital healthcare ecosystem, announce their collaboration to improve everyday therapy management and better address the needs of 60 million people living with ...
mehrRoche and the Zur Rose Group announce collaboration to offer innovative health journeys for people living with diabetes
Basel (ots) - - Roche, a world leader in integrated Personalised Diabetes Management, and the Zur Rose Group, provider of a European digital healthcare ecosystem, announce their collaboration to improve everyday therapy management and better address the needs of 60 million people living with diabetes in Europe [1] - ...
mehrZOE Study Reveals Eating a Plant Rich Diet Reduces Risk of Developing COVID-19 and Going to the Hospital
mehrRoche launches mySugr Pump Control within the mySugr app to simplify insulin pump therapy via smartphone
mehrRoche collaborates with Lilly to support people with diabetes on insulin pen therapy
Basel (ots) - ● Roche and Lilly will integrate data from Lilly’s connected insulin pen solution into the mySugr app in several countries. ● Both companies are dedicated to driving new possibilities to ease the complexity of daily decision making for people with diabetes on insulin pen therapy and their healthcare professionals. ● By collaborating with Lilly, ...
mehrSaxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12-17 years
Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda® is expanded for the treatment of obesity in adolescents aged 12-17 years.1 Over the last 20 years, the ...
mehrAdults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial
Bagsværd, Denmark (ots/PRNewswire) - Data presented at ENDO 2021 demonstrate clinically relevant weight loss, without weight regain, in people treated with semaglutide 2.4 mg vs placebo in combination with lifestyle intervention. New results from the STEP phase 3a clinical trial programme demonstrated weight loss ...
mehrRoche teams up with Diabeloop to advance the management of insulin pump therapy
Basel (ots/PRNewswire) - - The partnership will create new opportunities to lower the burden for people with diabetes in daily therapy management and to improve therapy outcomes1. - By partnering with Diabeloop, Roche steps into the field of automated insulin delivery (AID) representing a milestone in Roche's strategy of integrated Personalised Diabetes Management ...
mehrRoche teams up with Diabeloop to advance the management of insulin pump therapy
Basel (ots) - - The partnership will create new opportunities to lower the burden for people with diabetes in daily therapy management and to improve therapy outcomes(1). - By partnering with Diabeloop, Roche steps into the field of automated insulin delivery (AID) representing a milestone in Roche's strategy of integrated Personalised Diabetes Management (iPDM). Roche ...
mehrFORA® 6 Blood Glucose Monitors Help Diabetic Patients Monitor COVID-19 Risks
mehrSaxenda® Demonstrated Improvements in BMI and Body Weight in Adolescents With Obesity
Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk today announced that the New England Journal of Medicine published results of a phase 3 trial evaluating the investigational use of Saxenda® (liraglutide 3.0 mg) in adolescents (aged ...
mehrSwissmedic grants approval for pembrolizumab (KEYTRUDA®) in combination with axitinib (Inlyta®) for first-line therapy of advanced renal cell carcinoma(1)
Lucerne (ots) - - Swissmedic approval is based on a significant benefit in overall survival with pembrolizumab in combination with axitinib compared to sunitinib in the Phase III study KEYNOTE-426 - Pembrolizumab is the first PD-1 inhibitor that has ...
Ein Dokumentmehr
1